{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse+Large+Cell+Lymphoma+Relapsed%2FRefractory&page=3", "query": { "condition": "Diffuse Large Cell Lymphoma Relapsed/Refractory", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 592, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse+Large+Cell+Lymphoma+Relapsed%2FRefractory&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diffuse+Large+Cell+Lymphoma+Relapsed%2FRefractory&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T14:50:47.831Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00078949", "title": "Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "NCIC Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 849, "start_date": "2003-08-27", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2023-08-23", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 5, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078949" }, { "nct_id": "NCT02658968", "title": "Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed, Diffuse Large B-cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Betalutin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nordic Nanovector", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-03-02", "completion_date": "2021-07-10", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 3, "location_summary": "San Diego, California • San Francisco, California • Miami, Florida", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02658968" }, { "nct_id": "NCT02951156", "title": "Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Avelumab", "type": "BIOLOGICAL" }, { "name": "Utomilumab", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Azacitidine", "type": "OTHER" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-12-16", "completion_date": "2019-12-02", "has_results": true, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 9, "location_summary": "Duarte, California • Louisville, Kentucky • New Orleans, Louisiana + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02951156" }, { "nct_id": "NCT03610724", "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Tisagenlecleucel", "type": "BIOLOGICAL" }, { "name": "lymphodepleting chemotherapy", "type": "DRUG" }, { "name": "Bridging Therapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 34, "start_date": "2019-02-15", "completion_date": "2023-04-26", "has_results": true, "last_update_posted_date": "2024-06-20", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 8, "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03610724" }, { "nct_id": "NCT04792489", "title": "DALY II USA/ MB-CART2019.1 for DLBCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "Relapsed Diffuse Large B Cell Lymphoma", "High Grade B-cell Lymphoma (HGBCL)", "Primary Mediastinal B-cell Lymphoma (PMBCL)", "Transformed Lymphoma", "Central Nervous System Lymphoma", "Mantle Cell Lymphoma (MCL)", "Richter Transformation", "Transplant-ineligible 2nd Line DLBCL" ], "interventions": [ { "name": "zamtocabtagene autoleucel (MB-CART2019.1)", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Miltenyi Biomedicine GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2021-05-25", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04792489" }, { "nct_id": "NCT04566978", "title": "89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Large B-cell Lymphoma", "DLBCL" ], "interventions": [ { "name": "89Zr-DFO-REGN3767", "type": "DRUG" }, { "name": "PET/CT", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-09-11", "completion_date": "2025-03-21", "has_results": false, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566978" }, { "nct_id": "NCT00890747", "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Langerhans Cell Histiocytosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Aggressive NK-cell Leukemia", "AIDS-related Diffuse Large Cell Lymphoma", "AIDS-related Diffuse Mixed Cell Lymphoma", "AIDS-related Diffuse Small Cleaved Cell Lymphoma", "AIDS-related Immunoblastic Large Cell Lymphoma", "AIDS-related Lymphoblastic Lymphoma", "AIDS-related Malignancies", "AIDS-related Small Noncleaved Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Clear Cell Renal Cell Carcinoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extramedullary Plasmacytoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "HIV Infection", "HIV-associated Hodgkin Lymphoma", "Intraocular Lymphoma", "Isolated Plasmacytoma of Bone", "Light Chain Deposition Disease", "Mast Cell Leukemia", "Myelodysplastic Syndrome With Isolated Del(5q)", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloid/NK-cell Acute Leukemia", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Osteolytic Lesions of Multiple Myeloma", "Peripheral T-cell Lymphoma", "Plasma Cell Neoplasm", "Polycythemia Vera", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Primary Systemic Amyloidosis", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Renal Cell Cancer", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage IV Renal Cell Cancer", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-03-17", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 11, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890747" }, { "nct_id": "NCT00978432", "title": "Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "LBH589", "type": "DRUG" }, { "name": "Doublet (RAD001 and LBH589)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anne Beaven, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2012-02", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2016-11-25", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00978432" }, { "nct_id": "NCT01678443", "title": "Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "indium In 111 anti-CD45 monoclonal antibody BC8", "type": "BIOLOGICAL" }, { "name": "yttrium Y 90 anti-CD45 monoclonal antibody BC8", "type": "RADIATION" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "1999-09-01", "completion_date": "2018-09-27", "has_results": true, "last_update_posted_date": "2021-04-02", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01678443" }, { "nct_id": "NCT00156013", "title": "Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, B-Cell", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "CLOFARABINE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncology Specialists, S.C.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2005-09", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-11-09T14:50:47.831Z", "location_count": 1, "location_summary": "Park Ridge, Illinois", "locations": [ { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00156013" } ] }